Pearl Therapeutics

About:

Pearl develops a combination of products for the treatment of respiratory diseases, including chronic obstructive pulmonary disease.

Website: http://www.pearltherapeutics.com

Top Investors: Silicon Valley Bank, Nektar Therapeutics, 5AM Ventures, New Leaf Venture Partners, Oxford Finance LLC

Description:

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Total Funding Amount:

$256M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Morristown, New Jersey, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)pearltherapeutics.com

Founders:

Sarvajna Dwivedi

Number of Employees:

51-100

Last Funding Date:

2013-04-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai